CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 175 enrolled
Drug / intervention
Kisspeptin 1.6nmol/kg +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01667406
NCT01667406Phase 2Completed
CompareCT.gov

The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

Imperial College London·interventional·Posted Aug 17, 2012·Updated Jun 8, 2021

In Brief

A Phase 2 clinical trial evaluating Kisspeptin 1.6nmol/kg, Kisspeptin 3.2nmol/kg, and 5 other interventions for Infertility. Completed, enrolled 175 participants across 1 site.

Detailed Summary

We want to find out if kisspeptin is successful in stimulating oocyte maturation when it is used as a 'trigger' injection during IVF therapy for infertility.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfertility
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 17, 2012
Enrollment StartJun 1, 2012
Primary CompletionOct 11, 2016
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.9 years ago

Interventions

Kisspeptin 1.6nmol/kgdrug

single kisspeptin dose 1.6 nmol/kg subcutaneously

Kisspeptin 3.2nmol/kgdrug

single kisspeptin dose 3.2 nmol/kg subcutaneously

Kisspeptin 6.4nmol/kgdrug

single kisspeptin dose 6.4 nmol/kg subcutaneously

Kisspeptin 9.6nmol/kgdrug

single kisspeptin dose 9.6 nmol/kg subcutaneously

Kisspeptin 12.8nmol/kgdrug

single kisspeptin dose 12.8 nmol/kg subcutaneously

Kisspeptin 9.6 nmol/kg doubledrug

kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously

Kisspeptin 9.6 nmol/kg + salinedrug

kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart